March 6, 2013
Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for Cycloset® (bromocriptine mesylate) for the Management of Type 2 Diabetes
Experts conclude that favorable cardiovascular profile of Cycloset suggests it may be useful in the treatment of patients with type...
Read More
January 23, 2013
Santarus and VeroScience Announce Publication of Positive Data from Pivotal Cycloset® (bromocriptine mesylate) Efficacy Study
Cycloset add-on therapy provided significant improvement in glycemic control versus placebo in patients with type 2 diabetes poorly controlled on...
Read More
November 13, 2012
Santarus and VeroScience Announce Publication of New Analysis of Cycloset (bromocriptine mesylate) Cardiovascular Data in the Journal of the American Heart Association
In assessing cardiovascular safety in type 2 diabetes subjects, Cycloset demonstrated a significant 52% relative risk reduction in cardiovascular events...
Read More
November 4, 2010
Cycloset Data to Be Presented in Poster Session at 8th Annual World Congress on Insulin Resistance, Diabetes & CVD
SAN DIEGO & TIVERTON, R.I. --(BUSINESS WIRE)-- Santarus, Inc. (NASDAQ:SNTS) and VeroScience LLC today announced that analyses of 379-patient subset...
Read More
September 8, 2010
Santarus Licenses Novel Type 2 Diabetes Drug Cycloset
SAN DIEGO & BRISTOL, Tenn. & TIVERTON, R.I., Sep 08, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics,...
Read More
